<SUBMISSION>
<ACCESSION-NUMBER>0000950148-02-001450
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>2
<PERIOD>20020528
<ITEMS>5
<ITEMS>7
<FILING-DATE>20020528
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>ADVANCED BIOTHERAPY INC
<CIK>0000791833
<ASSIGNED-SIC>8731
<STATE-OF-INCORPORATION>NV
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-26323
<FILM-NUMBER>02663918
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>6355 TOPANGA CANYON BLVD
<STREET2>SUITE 510
<CITY>WOODLAND HILLS
<STATE>CA
<ZIP>91367
<PHONE>8188833956
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>6355 TOPANGA CANYON BLVD
<STREET2>SUITE 510
<CITY>WOODLAND HILLS
<STATE>CA
<ZIP>91367
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>ADVANCED BIOTHERAPY CONCEPTS INC
<DATE-CHANGED>19990524
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v82043e8vk.htm
<DESCRIPTION>FORM 8-K, 5/28/02
<TEXT>
<HTML>
<HEAD>
<TITLE>Advanced Biotherapy Form 8-K, 5/28/02</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<P align="center"><FONT size="2"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, DC 20549</B></FONT>

<P align="center"><FONT size="2"><B>FORM 8-K</B></FONT>

<P align="center"><FONT size="2"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934</B></FONT>

<P><FONT size="2">Date of Report (Date of earliest reported) May&nbsp;28, 2002
</FONT>
<P align="center"><FONT size="2">Advanced Biotherapy, Inc.</FONT>

<P>
<HR width="26%" align="center" size="1" noshade>
<P>

<P align="center"><FONT size="2"><FONT size="2">(Exact name of registrant as specified in its chapter)</FONT></FONT>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
        <TD width="32%">&nbsp;</TD>
        <TD width="1%">&nbsp;</TD>
        <TD width="33%">&nbsp;</TD>
        <TD width="1%">&nbsp;</TD>
        <TD width="33%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD align="center" valign="top"><FONT size="2">Delaware</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><FONT size="2">
0-26323
</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><FONT size="2">95-0402415</FONT></TD>
</TR>
<TR>
        <TD align="center" valign="top"><HR size="1" noshade></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><FONT size="2">
<HR size="1" noshade>
</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><HR size="1" noshade></TD>
</TR>
<TR valign="bottom">
        <TD align="center" valign="top"><FONT size="2">(State or other jurisdiction<BR>
of incorporation)</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><FONT size="2">
(Commission<BR>
File Number)
</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><FONT size="2">(IRS Employer<BR>
Identification No.)</FONT></TD>
</TR>
</TABLE>
</CENTER>
<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
        <TD width="48%">&nbsp;</TD>
        <TD width="1%">&nbsp;</TD>
        <TD width="2%">&nbsp;</TD>
        <TD width="48%">&nbsp;</TD>
        <TD width="1%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD align="center" valign="top"><FONT size="2">6355 Topanga Canyon Boulevard, Suite&nbsp;510<BR>
Woodland Hills, California</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD nowrap align="right" valign="top"><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="BOTTOM"><FONT size="2">
91367</FONT></TD>
        <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR>
        <TD align="center" valign="top"><HR size="1" noshade></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD nowrap align="right" valign="top"><FONT size="2">&nbsp;</FONT></TD>
        <TD align="right" valign="top"><FONT size="2">
<HR size="1" noshade></FONT></TD>
        <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
        <TD align="center" valign="top"><FONT size="2">(Address of principal<BR>
executive offices)</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD nowrap align="center" valign="top"><FONT size="2">&nbsp;</FONT></TD>
        <TD nowrap valign="top"  align="center"><FONT size="2">(Zip Code)</FONT></TD>
        <TD align="center" valign="top"><FONT size="2">&nbsp;</FONT></TD>

</TR>
</TABLE>
</CENTER>
<P><FONT size="2">Registrant&#146;s telephone number, including area code (818)&nbsp;883-6716
</FONT>
<P align="center"><FONT size="2">&nbsp;
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD></TD><TD colspan="8"><A HREF="#000">Item&nbsp;5. OTHER EVENTS.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#001">Item&nbsp;7. FINANCIAL STATEMENTS AND EXHIBITS</A></TD></TR>
<TR><TD colspan="9"><A HREF="#002">Signatures</A></TD></TR>
<TR><TD colspan="9"><A HREF="#003">INDEX TO EXHIBITS</A></TD></TR>
<TR><TD colspan="9"><A HREF="v82043exv99w1.htm">Exhibit 99.1</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>








<!-- link2 "Item&nbsp;5. OTHER EVENTS." -->
<DIV align="left"><A NAME="000"></A></DIV>
<P align="left"><FONT size="2">Item&nbsp;5. OTHER EVENTS.</FONT>

<P><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant published a press release on May&nbsp;28, 2002, which announced
that it has a patent application pending for the exclusive use of antibodies to
gamma interferon (IFN-g) for the treatment of Psoriasis, Vitiligo and Alopecia
Areata. A copy of such press release is incorporated herein by reference and
is attached as an exhibit to this Form&nbsp;8-K.
</FONT>
<!-- link2 "Item&nbsp;7. FINANCIAL STATEMENTS AND EXHIBITS" -->
<DIV align="left"><A NAME="001"></A></DIV>
<P align="left"><FONT size="2">Item&nbsp;7. FINANCIAL STATEMENTS AND EXHIBITS</FONT>

<P><FONT size="2">(c)&nbsp;Exhibits.
</FONT>
<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
        <TD width="12%">&nbsp;</TD>
        <TD width="5%">&nbsp;</TD>
        <TD width="83%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD nowrap align="center"><FONT size="1">Designation</FONT></TD>
        <TD><FONT size="1">&nbsp;</FONT></TD>
        <TD nowrap align="center"><FONT size="1">Description of Exhibit</FONT></TD>
</TR>
<TR valign="bottom">
        <TD nowrap align="center"><HR size="1" noshade></TD>
        <TD><FONT size="1">&nbsp;</FONT></TD>
        <TD nowrap align="center"><HR size="1" noshade></TD>
</TR>
<TR valign="bottom">
        <TD valign="top"><FONT size="2">99.1</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">
Press Release, dated May&nbsp;28, 2002</FONT></TD>
</TR>
</TABLE>
</CENTER>
<!-- link1 "Signatures" -->
<DIV align="left"><A NAME="002"></A></DIV>
<P align="center"><FONT size="2">Signatures</FONT>

<P><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
</FONT>
<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
        <TD width="45%">&nbsp;</TD>
        <TD width="5%">&nbsp;</TD>
        <TD width="50%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">
ADVANCED BIOTHERAPY, INC.<br>
(Registrant)</FONT></TD>
</TR>
<TR><TD>&nbsp;</TD></TR>

<TR valign="bottom">
        <TD valign="top"><FONT size="2">Date: May&nbsp;28, 2002</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">
By: /s/ Edmond Buccellato</FONT></TD>
</TR>
<TR>
        <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">
<HR size="1" noshade></FONT></TD>
</TR>
<TR valign="bottom">
        <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">
Edmond Buccellato, President and CEO</FONT></TD>
</TR>
</TABLE>
</CENTER>
<!-- link1 "INDEX TO EXHIBITS" -->
<DIV align="left"><A NAME="003"></A></DIV>
<P align="center"><FONT size="2">INDEX TO EXHIBITS</FONT>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
        <TD width="10%">&nbsp;</TD>
        <TD width="5%">&nbsp;</TD>
        <TD width="85%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD nowrap align="center"><FONT size="1">Exhibit</FONT></TD>
        <TD><FONT size="1">&nbsp;</FONT></TD>
        <TD nowrap align="center"><FONT size="1">Description</FONT></TD>
</TR>
<TR valign="bottom">
        <TD nowrap align="center"><HR size="1" noshade></TD>
        <TD><FONT size="1">&nbsp;</FONT></TD>
        <TD nowrap align="center"><HR size="1" noshade></TD>
</TR>
<TR valign="bottom">
        <TD valign="top"><FONT size="2">99.1</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">
Text of Press Release, dated May&nbsp;28, 2002</FONT></TD>
</TR>
</TABLE>
</CENTER>
<P align="center"><FONT size="2">&nbsp;
</FONT>

</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>v82043exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Advanced Biotherapy Form 8-K, 5/28/02</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<P><FONT size="2">EXHIBIT 99.1
</FONT>
<P><FONT size="2"><B>Advanced Biotherapy, Inc. Discloses Patent Pending for Exclusive Use of
Antibodies to Gamma Interferon in the Treatment of Psoriasis, Vitiligo and
Alopecia Areata</B>
</FONT>
<P><FONT size="2">WOODLAND HILLS, Calif.&#151; (BW HealthWire)&#151;May&nbsp;28, 2002&#151; Advanced Biotherapy, Inc.
(OTCBB: ADBV-news) announced today that it has a patent application pending for the
exclusive use of any form of antibody to gamma interferon (IFN-g) for the
treatment of Psoriasis, Vitiligo and Alopecia Areata. As previously reported,
The United States Patent and Trademark Office (USPTO)&nbsp;issued U.S. Patent No.
6,333,032 to the Company for the exclusive use of IFN-g antibodies &#151; including
humanized and fully human, as well as other antibody types &#151; to treat Multiple
Sclerosis, Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Psoriatic
Arthritis (a form of psoriasis) and Ankylosing Spondylitis. The company also
has a patent application pending for the exclusive use of any form of antibody
to gamma interferon (IFN-g) for the treatment of Crohn&#146;s Disease.
</FONT>
<P><FONT size="2">Commenting on this announcement, Mr.&nbsp;Edmond Buccellato, President and Chief
Executive Officer, stated, &#147;This additional important pending patent
application covering these autoimmune diseases further enhances our patent
portfolio which already covers treatment of several autoimmune diseases.&#148;
</FONT>
<P><FONT size="2">Psoriasis is a chronic skin disease characterized by periodic flare-ups of a
clearly defined reddish, scaly rash that is most often located on the elbows,
knees, scalp, ears, and lower back. Nails are affected in various ways in many
people with psoriasis, and approximately 10-15% of those with the condition
will develop inflammatory arthritis (Psoriatic Arthritis). Simon Skurkovich,
M.D., Vice President of Research and Development and pioneer of anticytokine
therapy for autoimmune conditions stated, &#147;That in pilot studies, after a full
7-day course of therapy, papular psoriatic lesions disappeared.&#148; According to
the National Psoriasis Foundation, Psoriasis affects more than 7&nbsp;million
Americans.
</FONT>
<P><FONT size="2">Vitiligo is a condition that affects skin coloration. With Vitiligo, the
special cells that make pigment (the substance that controls skin color) are
destroyed, resulting in patches of discolored skin. Vitiligo often affects the
chest and abdomen, but may be found on the face around the mouth, nostrils and
eyes. This condition usually occurs in people suffering from Type 1 diabetes.
There is no specific treatment for Vitiligo. Dr.&nbsp;Skurkovich further commented,
&#147;That on day 10 after a short-course of therapy in a pilot study, all patients
showed loss of well-defined borders between normal and hypopigmented skin.&#148;
According to the Vitiligo Research Foundation, this condition affects about 1%
to 2% of the US population, or about 3 to 6&nbsp;million people. In some countries,
the incidence is even higher. Worldwide, there are thought to be more than 100
million people with the condition.
</FONT>
<P><FONT size="2">Alopecia Areata is a highly unpredictable, autoimmune skin disease resulting in
the loss of hair on the scalp and elsewhere on the body. In patients suffering
from Alopecia Areata, the affected hair follicles are mistakenly attacked by a
person&#146;s own immune system (white blood cells), resulting in the arrest of the
hair growth stage. Alopecia Areata usually starts with one or more small,
round, smooth bald patches on the scalp and can progress to total baldness.
Dr.&nbsp;Skurkovich concluded by stating, &#147;That in a pilot study for this disease,
four weeks after a short-course of therapy, patients developed thin depigmented
fine hair. After another 2-4&nbsp;weeks, intensive growth of normal hair was
observed in the treated lesions.&#148; According to the National Alopecia Areata
Foundation, this common but very challenging and capricious disease affects
approximately 1.7&nbsp;percent of the population overall, including more than 4
million people in the United States alone.
</FONT>
<P><FONT size="2">Statements made in this news release, other than statements of historical fact,
are forward-looking statements and are subject to a number of uncertainties
that could cause actual results to differ materially
</FONT>
<P align="center"><FONT size="2">&nbsp;
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<P><FONT size="2">from the anticipated results or other expectations expressed in our
forward-looking statements. The risks and uncertainties which may affect the
development, operations and results of our business include, but are not
limited to the following: risks associated with clinical trials, the
uncertainties of research and product development programs, the uncertainties
of the regulatory approval process, the risks of competitive products, the
risks of our current capital resources, the uncertainties as to the
availability of future capital and our future capital requirements, and the
risks associated with the extent and breadth of the Company&#146;s patent portfolio.
The foregoing discussion of the effect of the patent issued and pending
involves risks and uncertainties, including but not limited to the risks that
third parties may be successful in challenging such patents; or that granted
claims may be held invalid or interpreted differently by a court of law; or
that new technologies will be developed that are superior in treating the
diseases targeted by Advanced Biotherapy, Inc. Readers are cautioned not to
place reliance on these forward-looking statements, which speak only as of the
date the statements were made. See the Company&#146;s public filings with the
Securities and Exchange Commission for further information about risks and
uncertainties that may affect the Company and the results or expectations
expressed in our forward-looking statements, including the section captioned
&#147;Factors That May Affect The Company&#148; contained in the Company&#146;s Annual Report
on Form&nbsp;10-KSB for the fiscal year ended December&nbsp;31, 2001.
</FONT>
<P>
<HR size="1" width="18%" align="left" noshade>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">
<TR valign="top">
      <TD width="1%" align="left" nowrap><FONT size="2"><I>&nbsp;</I></FONT></TD>
        <TD width="1%"><FONT size="2">&nbsp;</FONT></TD>
        <TD width="98%"><FONT size="2"><I>Contact:</I></FONT></TD>
</TR>
</TABLE>
<P><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Advanced Biotherapy, Inc.<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Edmond Buccellato, 818/883-6716, Ext. 2<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Keith Gregg, Business Development, Ext. 3<BR>
E-mail: ed@advancedbiotherapy.com<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;keith@advancedbiotherapy.com<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Website: www.advancedbiotherapy.com
</FONT>

<P align="center"><FONT size="2">&nbsp;</FONT>


</BODY>
</HTML>

</TEXT>
</DOCUMENT>
</SUBMISSION>
